Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Jan 27, 2021Data include the first presentation of results from the pivotal Phase 3 CLEAR study (KEYNOTE-581/Study 307) evaluating KEYTRUDA® (pembrolizumab) plus LENVIMA and LENVIMA plus everolimusEisai will present four abstracts at the virtual Genitourinary Cancers Symposium 2021 (#GU21) from February 11-13, 2021. These investigational data include a late-breaking oral presentation from...
Jan 11, 2021Eisai will present five abstracts across four tumor types at the Gastrointestinal Cancers Symposium (#GI21), which is being held virtually from January 15-17, 2021. Investigational data on the...
-
Dec 16, 2020First Overall Survival Analysis for KEYTRUDA Plus LENVIMA Combination in a Phase 3 Study in Advanced Endometrial Cancer
KENILWORTH, N.J., and WOODCLIFF LAKE, N.J., Dec. 16, 2020 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced that the pivotal Phase 3...
-
Dec 8, 2020Latest Initiative of #ThisIsMBC "Perseverance" to be Unveiled at the 2020 Virtual San Antonio Breast Cancer Symposium
Eisai Inc. and METAvivor today announced the launch of Perseverance, a new initiative of the #ThisIsMBC campaign. Perseverance showcases imagery of a diverse group of 12 participants capturing the...
- Nov 20, 2020Results support 24 mg as the starting dose for LENVIMA in patients with radioactive iodine-refractory differentiated thyroid cancer
Eisai announced results from Study 211 evaluating the safety and efficacy of LENVIMA, an orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, at two starting doses:...